SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-053664
Filing Date
2022-04-29
Accepted
2022-04-29 16:36:58
Documents
5
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2213754-1_def14a.htm DEF 14A 525264
2 GRAPHIC lg_protalix-4c.jpg GRAPHIC 14927
3 GRAPHIC sg_eyalrubin-bw.jpg GRAPHIC 4887
4 GRAPHIC tm2213754d1-px_page01bwlr.jpg GRAPHIC 419360
5 GRAPHIC tm2213754d1-px_page02bwlr.jpg GRAPHIC 617741
  Complete submission text file 0001104659-22-053664.txt   1982432
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 22876348
SIC: 2836 Biological Products, (No Diagnostic Substances)